MedTrace Logo

Atazavanir/Ritonavir-based HAART in Children

NCT01656109 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-08-26

No results posted yet for this study

Summary

There are no data on efficacy, safety and pharmacokinetics of ATV/r-based HAART in HIV-infected Asian children. Therefore, the investigators aim to evaluate the pharmacokinetics, efficacy and safety of ATV/r-based HAART in Thai HIV-infected children.

Conditions

Interventions

DRUG

boosted atazanavir (ATV/r)

ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline

Sponsors & Collaborators

  • amfAR, The Foundation for AIDS Research

    collaborator OTHER

  • National Health Security Office, Thailand

    collaborator OTHER

  • The Thai Government Pharmaceutical Organization (GPO)

    collaborator UNKNOWN

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Torsak Bunupuradah, MD · The HIV Netherlands Australia Thailand Research Collaboration

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656109 on ClinicalTrials.gov